Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel A. Ruiz-Torres"'
Autor:
Daniel A. Ruiz-Torres, Jillian F. Wise, Brian Yinge Zhao, Joao Paulo Oliveira-Costa, Sara Cavallaro, Peter M. Sadow, Jacy Fang, Osman Yilmaz, Amar Patel, Christopher Loosbroock, Moshe Sade-Feldman, Daniel L. Faden, Shannon L. Stott
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
The potent immunostimulatory effects of toll-like receptor 8 (TLR8) agonism in combination with PD-1 blockade have resulted in various preclinical investigations, yet the mechanism of action in humans remains unknown. To decipher the combinatory mode
Externí odkaz:
https://doaj.org/article/35fa217099bf401997c467b0569a1902
Autor:
Daniel Felipe Silgado-Guzmán, Mariana Angulo-Aguado, Adrien Morel, María José Niño-Orrego, Daniel-Armando Ruiz-Torres, Nora Constanza Contreras Bravo, Carlos Martin Restrepo, Oscar Ortega-Recalde, Dora Janeth Fonseca-Mendoza
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
In genes related to drug pharmacokinetics, molecular variations determine interindividual variability in the therapeutic efficacy and adverse drug reactions. The assessment of single-nucleotide variants (SNVs) is used with growing frequency in pharma
Externí odkaz:
https://doaj.org/article/10867b9155d44fb99926fc3ee2a4c058
Autor:
Mariana, Angulo-Aguado, Karen, Panche, Caroll Andrea, Tamayo-Agudelo, Daniel-Armando, Ruiz-Torres, Santiago, Sambracos-Parrado, Maria Jose, Niño-Orrego, Nathaly, Páez, Laura B, Piñeros-Hernandez, Luisa-Fernanda, Castillo-León, Juan Mauricio, Pardo-Oviedo, Katherine Parra, Abaunza, Paul, Laissue, Nora, Contreras, Carlos Alberto, Calderón-Ospina, Dora Janeth, Fonseca-Mendoza
Publikováno v:
Journal of Personalized Medicine
Clopidogrel, an oral platelet P2Y12 receptor blocker, is used in the treatment of acute coronary syndrome. Interindividual variability in treatment response and the occurrence of adverse effects has been attributed to genetic variants in CYP2C19. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f4a1ee31e5a1ed075b0b1a37549111fb
https://pubmed.ncbi.nlm.nih.gov/34065778
https://pubmed.ncbi.nlm.nih.gov/34065778
Autor:
Nora Contreras, Nathaly Páez, Dora Janeth Fonseca-Mendoza, Caroll Tamayo-Agudelo, Santiago Sambracos-Parrado, Juan Mauricio Pardo-Oviedo, Karen Panche, Maria Jose Niño-Orrego, Katherine Parra Abaunza, Daniel Armando Ruiz-Torres, Laura B. Piñeros-Hernández, Carlos Alberto Calderón-Ospina, Luisa Fernanda Castillo-León, Paul Laissue, Mariana Angulo-Aguado
Publikováno v:
Journal of Personalized Medicine
Volume 11
Issue 5
Journal of Personalized Medicine, Vol 11, Iss 400, p 400 (2021)
Volume 11
Issue 5
Journal of Personalized Medicine, Vol 11, Iss 400, p 400 (2021)
Clopidogrel, an oral platelet P2Y12 receptor blocker, is used in the treatment of acute coronary syndrome. Interindividual variability in treatment response and the occurrence of adverse effects has been attributed to genetic variants in CYP2C19. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e7cb13ebce266d996f1e4c1e7b384b
https://doi.org/10.3390/jpm11050400
https://doi.org/10.3390/jpm11050400